NCBiotech News

The NCBiotech Agriculture Sector Development team is partnering with local agriculture organizations to highlight women in agriculture across North Carolina.

Precision BioSciences, a genome-editing company based in Durham, has received authorization from the U.S. Food and Drug Administration to advance its second genome-edited cancer therapy to clinical trials.  

Durham-based Arbiom is challenging the world of animal feed by utilizing wood waste as a source of protein.

Durham’s Mycovia Pharmaceuticals is one of nine startups scrambling for last-minute votes in the “Buzz of BIO” Late Stage Leaders competition, part of the BIO Investor Forum taking place in San Francisco this October.

RFPi, a Greenville medical device company, has landed a groundbreaking $1.49 million NIH grant with ECU as its academic research partner.

The North Carolina Biotechnology Center has launched the inaugural installment of its new podcast series, “Transformation Talk.” The 22-minute program, hosted by Jim Shamp, NCBiotech’s director of public relations, features former Biotech Center president Charles Hamner Jr., D.V.M., and Bill Bullock, senior vice president of economic development and statewide operations.

Accelerated Enrollment Solutions, a business unit of Wilmington’s Pharmaceutical Product Development, has purchased the clinical research site business of clinical trial development company Bioclinica.

Durham contract services organization KBI Biopharma is working with two other companies to develop a novel therapy to treat inflammatory diseases.

North Carolina is taking an increasing leadership role in precision health as we apply new technologies to our deepening understanding of how people’s genetic makeup and other factors impact their wellbeing.

Registration is open for the Sept. 25 and 26 "Invest in Cures & Rare Disease Forum," bringing together potential investors, collaborators and NC therapeutics developers to find new ways to deal with orphan diseases.

Viralgen, a Spanish contract development and manufacturing organization half owned by AskBio of Research Triangle Park, has gained vital regulatory status in Europe for producing gene therapies using AskBio’s manufacturing process.

Durham-based Aerie Pharmaceuticals, a developer of therapies for eye diseases, has begun patient dosing in a first-in-human clinical trial of an implantable drug for treating two retinal diseases.

The 11th annual Ag Innovation Showcase will connect the relationship of health in food production and the environment. The Guthrie in Minneapolis will be hosting the Showcase September 9-11, offering expert panels with rapid-fire discussions, spotlight sessions, and representation from multiple agribusiness companies.

Thermo Fisher Scientific has a new virtual reality training facility that will mimic real-world operating environments as a way to train new employees on the sterile injectibles drug production lines.

North Carolina’s Raleigh-Durham metro area, a.k.a. the Research Triangle, has the nation’s fourth-leading life science base among major metro hubs, according to a new report.